What Is Tesofensine?
Tesofensine is not a peptide. It is a small synthetic molecule, originally coded NS2330, that blocks the reuptake of three brain chemicals at once: noradrenaline, dopamine and serotonin. That makes it a "triple monoamine reuptake inhibitor." It ends up on peptide sites and clinic menus because it is sold through the same research-chemical channels, usually as 500 µg capsules, and marketed for weight loss.
It started as a drug for Parkinson's and Alzheimer's disease. Developed by the Danish company NeuroSearch with Boehringer Ingelheim, it did not work well enough for either condition, but patients in those trials kept losing weight without trying.[1] NeuroSearch then repurposed it for obesity.
The weight-loss result from that phase 2 work was strong for its time. The trouble is that the program stopped at phase 2. No phase 3 obesity trial appears on ClinicalTrials.gov, and no regulator we can verify has approved it. Most of the human data comes from four 14-week Parkinson's and Alzheimer's trials and one 24-week obesity trial published in 2008.
- Tesofensine is a small-molecule drug that blocks the reuptake of noradrenaline, dopamine and serotonin. It is not a peptide.
- In a 2008 phase 2 trial of 203 people with obesity, 0.5 mg once daily plus diet produced 9.2% weight loss at 24 weeks, against 2.0% for placebo plus diet.
- It raised heart rate (7.4 beats per minute at 0.5 mg), and The Lancet later issued an expression of concern about how that trial reported side effects.
- It has a very long half-life, about 234 hours (roughly 10 days), so it builds up and clears slowly.
- It is not FDA-approved, never completed phase 3 for obesity, and is banned in competition by WADA as a stimulant.
| Common Name | Tesofensine |
| Code Name | NS2330 |
| Formula / Molecular Weight | C17H23Cl2NO / about 328 Da |
| Class | Small molecule, triple monoamine reuptake inhibitor (not a peptide) |
| Original Developer | NeuroSearch A/S, with Boehringer Ingelheim |
| Route in Trials | Oral tablet, once daily |
| Doses in Trials | 0.125 mg to 1.0 mg daily; 2 mg daily for one week in a mechanism study |
| Half-life | About 234 hours (parent drug); about 374 hours (main metabolite) |
| Furthest Trial Stage | Phase 2 |
| FDA Status | Not approved for any indication |
| WADA Status | Prohibited in competition (S6 stimulants) |
How Does Tesofensine Work?
Nerve cells release noradrenaline, dopamine and serotonin, then pull them back in through transporter proteins. Tesofensine blocks those transporters, so more of each chemical stays active between nerve cells. A PET scan study showed how much: at doses of 0.125 to 1 mg daily, tesofensine occupied 18% to 77% of the brain's dopamine transporters, with half the maximum effect reached at about 0.25 mg.[2]
In people, the effect is mostly on appetite. In a two-week trial in 32 overweight men told to keep eating and moving as usual, tesofensine produced 1.8 kg more weight loss than placebo, raised feelings of fullness and lowered expected food intake.[3] It did not raise 24-hour energy expenditure overall, though it increased fat burning and nighttime energy use slightly.[3] So it is mainly an appetite suppressant, with a small metabolic effect on top.
That appetite effect fades. In the 24-week trial, a satiety score rose by week 12 and then drifted back down as weight came off. When the drug was stopped, satiety returned to baseline even though people were still lighter, and restarting the drug raised it again.[4]
Why it is grouped with older diet drugs
Raising noradrenaline and dopamine is how stimulant-type appetite suppressants work, and it is also why they raise heart rate. Pharmacologically, tesofensine sits closer to drugs like sibutramine and bupropion than to GLP-1 medicines such as semaglutide, which act on gut-hormone receptors.
What the Clinical Evidence Actually Shows
The main obesity trial (2008). This is the study behind almost every tesofensine claim. Five Danish obesity centres randomized 203 people with a BMI of 30 to 40 to placebo or tesofensine 0.25 mg, 0.5 mg or 1.0 mg once daily for 24 weeks, all on a calorie-restricted diet. 161 (79%) finished. Average weight loss was:[5]
| Group | Weight loss at 24 weeks |
|---|---|
| Placebo + diet | 2.0% |
| Tesofensine 0.25 mg + diet | 4.5% |
| Tesofensine 0.5 mg + diet | 9.2% |
| Tesofensine 1.0 mg + diet | 10.6% |
The authors suggested 0.5 mg "might" produce twice the weight loss of drugs approved at the time, and said the findings needed confirmation in phase 3.[5] That confirmation never came.
The Parkinson's and Alzheimer's trials. A pooled analysis of four 14-week trials (740 people on tesofensine, 228 on placebo, no diet program) found weight changes of +0.5% on placebo and -0.5%, -0.9%, -1.8% and -2.8% on 0.125, 0.25, 0.5 and 1.0 mg.[6] That is about 4% placebo-adjusted loss at the top dose without trying, which is what prompted the switch to obesity.
The neurological results themselves were weak. In early Parkinson's (261 people), no dose beat placebo at 14 weeks.[10] In advanced Parkinson's, 0.5 mg and 0.25 mg showed modest gains on single measures, but there was no clear dose-response.[11]
Tesomet (tesofensine plus metoprolol). A later developer, Saniona, paired 0.5 mg tesofensine with 50 mg of the beta-blocker metoprolol to cancel out the heart rate rise, an approach tested earlier in rats.[9] In 21 adults with hypothalamic obesity (weight gain after brain injury, often from tumors), Tesomet gave 6.3% more weight loss than placebo over 24 weeks, without a difference in heart rate or blood pressure.[8] That is one small trial in a rare condition. Two US Tesomet trials planned for late 2021, in hypothalamic obesity and Prader-Willi syndrome, are listed on ClinicalTrials.gov as withdrawn with zero participants.
What the Evidence Does Not Show
- Long-term results. The longest controlled data is 24 weeks. Nothing shows whether weight stays off, or what happens to heart rate and mood over years.
- Phase 3 confirmation. No large phase 3 obesity trial has been published or registered on ClinicalTrials.gov (searched October 2026).
- How it compares with modern drugs. No trial has compared tesofensine with semaglutide, tirzepatide or any GLP-1 medicine.
- Results with online products. Every trial used pharmaceutical-grade tablets. None used the capsules sold online.
- Benefit for ADHD, focus or energy. No trial has tested it for these uses.
Typical Dosing — What the Research Has Used
No approved dose
Tesofensine has no approved dose anywhere we could verify. The figures below describe what clinical trials gave participants under medical supervision. They are not dosing guidance.
Doses used. Trials used 0.125, 0.25, 0.5 and 1.0 mg once daily by mouth.[5][6] One short mechanism study gave 2.0 mg daily for seven days, then 1.0 mg for seven more.[3] In the obesity trial, 1.0 mg added little weight loss over 0.5 mg (10.6% against 9.2%), and side effects tended to rise with dose in the Parkinson's trials.[5][11] The 500 µg capsules sold online match the 0.5 mg trial dose, but that does not make their contents equivalent to the trial tablets.
When to take it. The trials gave one dose daily; the published abstracts do not specify a time of day. Insomnia was among the most common side effects,[5] which is why community-reported protocols usually take it in the morning. That is a practical habit, not a trial finding.
Cycle length. No study has tested on/off cycles. Trials ran continuously for 14 or 24 weeks, and one ran a second 24-week open-label course after a drug-free break of about 12 weeks.[4] The appetite effect wore off after stopping and returned on restarting.[4]
Why the half-life matters. In 320 Alzheimer's patients, tesofensine's half-life was about 234 hours and its main metabolite's about 374 hours.[12] That means each dose stays around for weeks, levels take several weeks to plateau, and effects and side effects linger after stopping. The same study found that women with reduced kidney function had about 62% higher exposure than men with normal kidneys.[12]
Side Effects
The side effect picture comes from a small number of trials, and how fully those trials reported harms has been questioned.
What the trials reported. In the 24-week obesity trial, the most common side effects were dry mouth, nausea, constipation, hard stools, diarrhoea and insomnia. Blood pressure did not rise significantly at 0.25 or 0.5 mg, but heart rate rose by 7.4 beats per minute at 0.5 mg.[5] Across the 14-week neurological trials, heart rate rose in step with dose, from 2.1 to 6.8 beats per minute.[6] A review noted significant blood pressure increases at the highest dose tested.[1] In advanced Parkinson's, digestive and neuropsychiatric side effects were more frequent than on placebo, especially at higher doses.[11] In the Tesomet trial, sleep problems (50% against 13% on placebo), dry mouth (43% against 0%) and headache (36% against 0%) were common, and one person stopped because of worsened anxiety.[8]
The reporting problem. In 2013 The Lancet published an expression of concern about the 2008 trial, and the trial's authors published a letter in the same journal titled "Under-reporting of adverse effects of tesofensine."[7] Treat the original side effect figures as a floor, not a complete list.
Abuse potential. Because it raises dopamine, abuse is a reasonable worry. In a crossover study of 52 recreational stimulant users, a single dose of tesofensine felt no different from placebo and less "drug-like" than 30 mg of D-amphetamine, with effects no greater than bupropion or atomoxetine.[13] That was a single-dose test, not long-term use.
Withdrawal. No study has described a withdrawal syndrome. What is documented is that appetite returned to baseline after stopping.[4]
People with heart disease, high blood pressure, anxiety, a history of depression or bipolar disorder, kidney disease, or who take antidepressants or stimulants have the most reason to talk to a physician before using an unregulated drug that acts on all three monoamines. No interaction studies with those drugs have been published.
Regulatory & Access Status
Access status as of October 2026
Tesofensine is not FDA-approved for any indication. We could not verify approval by any other regulator, so we do not state one. One clinic on our directory currently lists tesofensine among the treatments it offers.
In the US, tesofensine reaches buyers as "research use only" capsules or, according to a 2026 anti-doping study, as a product marketed online as a dietary supplement.[14] Neither route involves FDA review of safety, dose or purity.
For athletes, the same study notes that tesofensine is classified under S6 stimulants on the WADA Prohibited List and is banned in competition only. After a single 483 µg dose, it could be detected in urine for up to about 500 hours.[14]
Sourcing & Safety
If you are weighing tesofensine anyway, the product question comes before the dose question:
- Third-party testing. Look for a dated certificate of analysis from a named independent lab for your batch, with HPLC purity and mass spectrometry identity confirming tesofensine (about 328 Da).
- Measured content per capsule. Low-dose capsules are easy to under- or over-fill. The trials showed side effects rising with dose.
- Medical oversight. Heart rate and blood pressure monitoring were part of every trial. That is harder to replicate at home.
Treat as red flags any product that calls tesofensine a "peptide," claims FDA approval, cites phase 3 results, or promises a specific number of pounds per month.
What Makes Tesofensine Different
Most weight-loss compounds on our site are peptides that act on gut-hormone receptors. Tesofensine is a pill that works on the brain's neurotransmitters, more like the older appetite suppressants. Its trial data looked strong for 2008, but the field has moved on to drugs with phase 3 programs and approvals behind them.
Tesofensine vs. Other Weight-Loss Options
| Parameter | Tesofensine | Semaglutide | Tirzepatide |
|---|---|---|---|
| What it is | Small molecule (not a peptide) | Peptide | Peptide |
| How it works | Blocks reuptake of noradrenaline, dopamine and serotonin | GLP-1 receptor agonist | GLP-1 and GIP receptor agonist |
| Route | Oral, once daily | Weekly injection | Weekly injection |
| Furthest trial stage for obesity | Phase 2 | Approved | Approved |
| FDA status | Not approved | FDA-approved for chronic weight management | FDA-approved for chronic weight management |
FAQ
Is tesofensine a peptide?
No. Tesofensine is a small synthetic molecule (molecular weight about 328) built on a tropane ring, not a chain of amino acids. It is sold alongside peptides by research vendors and some clinics, but chemically and pharmacologically it belongs with drugs like bupropion and sibutramine, which act on brain neurotransmitters.
What dose of tesofensine was used in studies?
The main obesity trial gave 0.25 mg, 0.5 mg or 1.0 mg by mouth once daily for 24 weeks. The 0.5 mg dose produced 9.2% weight loss against 2.0% on placebo, and 1.0 mg produced 10.6% but with more side effects. A short mechanism study used 2 mg daily for one week. These are trial doses, not a recommendation, and no regulator has approved any dose.
When is the best time to take tesofensine?
The published trials gave it once daily and their abstracts do not specify a time of day. Insomnia was one of the most common side effects in the trials, which is why community-reported protocols usually take it in the morning. With a half-life of roughly 10 days, the timing of each dose matters less than with short-acting drugs, because blood levels stay fairly steady.
How long is a tesofensine cycle?
There is no tested 'cycle'. Trials ran continuously for 14 or 24 weeks, and one study added a second 24-week open-label course after a drug-free break of about 12 weeks. When the drug was stopped, the appetite-suppressing effect went back to baseline. Because the drug lasts so long in the body, it also takes several weeks to build up and to clear.
What are the side effects of tesofensine?
In the 24-week obesity trial the most common were dry mouth, nausea, constipation, hard stools, diarrhoea and insomnia. Heart rate rose by 7.4 beats per minute at 0.5 mg. Sleep problems, headache and anxiety also appeared in a later trial. In 2013 The Lancet published an expression of concern about the main trial, and its authors published a letter titled 'Under-reporting of adverse effects of tesofensine.'
Is tesofensine FDA approved or legal?
Tesofensine is not FDA-approved for any use. It is sold online as a research chemical or a dietary supplement, and neither label means the FDA has reviewed its safety or effectiveness. It is on the World Anti-Doping Agency's prohibited list as a stimulant, banned in competition.
Related Peptides & Comparisons
If you are comparing weight-loss options, semaglutide, tirzepatide and liraglutide are the approved peptide drugs with large trials behind them, and retatrutide is the most-watched one still in development. Among research compounds, AOD-9604 and 5-Amino-1MQ are often sold alongside tesofensine. Our guide to peptides for weight loss covers the wider field.
References
- Bello NT, Zahner MR. "Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity." Curr Opin Investig Drugs. 2009;10(10):1105-16. PMID: 19777399
- Appel L, Bergström M, Buus Lassen J, et al. "Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET." Eur Neuropsychopharmacol. 2014;24(2):251-61. PMID: 24239329
- Sjödin A, Gasteyger C, Nielsen AL, et al. "The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men." Int J Obes (Lond). 2010;34(11):1634-43. PMID: 20479765
- Gilbert JA, Gasteyger C, Raben A, et al. "The effect of tesofensine on appetite sensations." Obesity (Silver Spring). 2012;20(3):553-61. PMID: 21720440
- Astrup A, Madsbad S, Breum L, et al. "Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial." Lancet. 2008;372(9653):1906-1913. PMID: 18950853
- Astrup A, Meier DH, Mikkelsen BO, et al. "Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease." Obesity (Silver Spring). 2008;16(6):1363-9. PMID: 18356831
- Astrup A, Madsbad S, Breum L, et al. "Under-reporting of adverse effects of tesofensine." Lancet. 2013;382(9887):127. PMID: 23849924
- Huynh K, Klose M, Krogsgaard K, et al. "Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity." Eur J Endocrinol. 2022;186(6):687-700. PMID: 35294397
- Bentzen BH, Grunnet M, Hyveled-Nielsen L, et al. "Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats." Obesity (Silver Spring). 2013;21(5):985-92. PMID: 23784901
- Hauser RA, Salin L, Juhel N, et al. "Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease." Mov Disord. 2007;22(3):359-65. PMID: 17149725
- Rascol O, Poewe W, Lees A, et al. "Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study." Arch Neurol. 2008;65(5):577-83. PMID: 18474731
- Lehr T, Staab A, Tillmann C, et al. "Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease." Br J Clin Pharmacol. 2007;64(1):36-48. PMID: 17324246
- Schoedel KA, Meier D, Chakraborty B, et al. "Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users." Clin Pharmacol Ther. 2010;88(1):69-78. PMID: 20520602
- Krug O, Thomas A, Thevis M. "Investigations Into the Metabolism and Elimination of Tesofensine in Human Urine." Drug Test Anal. 2026;18(9):1163-1173. PMID: 42320973
This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any treatment.





